Emibetuzumab
- CAS No.
- 1365287-97-3
- Chemical Name:
- Emibetuzumab
- Synonyms
- LY2875358;Emibetuzumab;Emibetuzumab (anti-MET);Research Grade Emibetuzumab;Research Grade Emibetuzumab(DHC34201)
- CBNumber:
- CB28080907
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | MO4K3GDN1I |
Emibetuzumab Chemical Properties,Uses,Production
Description
Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.
Uses
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].
Clinical Use
A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.
in vivo
Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models[1].
| Animal Model: | Athymic nude mice (U87MG tumor xenograft model)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection, once a week for 5 weeks. |
| Result: | Demonstrated a significant inhibition of tumor growth. |
| Animal Model: | Athymic nude mice (MKN45 xenograft tumor model)[1]. |
| Dosage: | 10 or 20 mg/kg |
| Administration: | Intravenous injection, single. |
| Result: | Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days. |
| Animal Model: | Athymic nude mice (MET-amplified xenograft mouse tumor models)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection, once a week for 3, 5 or 6 weeks. |
| Result: | Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors. |
References
[1] Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. DOI:10.1158/1078-0432.CCR-14-0543
Emibetuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Emibetuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 71826 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24963 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9868 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 6783 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| Shanghai Aladdin Biochemical Technology Co.,Ltd. | 400-6206333 13167063860 | anhua.mao@aladdin-e.com | China | 48140 | 58 |
